Related references
Note: Only part of the references are listed.Ribosomal Protein S6: A Potential Therapeutic Target against Cancer?
Yong Weon Yi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma
Amir Barzegar Behrooz et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumors
Ashlyn Parkhurst et al.
CELL DEATH & DISEASE (2022)
Tumor-Associated Macrophages in Gliomas-Basic Insights and Treatment Opportunities
Johannes K. Andersen et al.
CANCERS (2022)
Role and regulation of autophagy in cancer
Ravichandran Rakesh et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2022)
Recent advances and limitations of mTOR inhibitors in the treatment of cancer
Eunus S. Ali et al.
CANCER CELL INTERNATIONAL (2022)
The effects of painless nerve growth factor on human microglia polarization
Lucia Lisi et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2022)
Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment
Xianbo Wu et al.
FRONTIERS IN PHARMACOLOGY (2022)
Cadherin Expression and EMT: A Focus on Gliomas
Carolina Noronha et al.
BIOMEDICINES (2021)
The Anti-Non-Small Cell Lung Cancer Cell Activity by a mTOR Kinase Inhibitor PQR620
Jian-hua Zha et al.
FRONTIERS IN ONCOLOGY (2021)
Integrin Signaling in Glioma Pathogenesis: From Biology to Therapy
Aleksandra Ellert-Miklaszewska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
PDIA3 Expression in Glioblastoma Modulates Macrophage/Microglia Pro-Tumor Activation
Marta Chiavari et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
Tian Tian et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment
Dennis Heinzen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
mTOR: Role in cancer, metastasis and drug resistance
Avaniyapuram Kannan Murugan
SEMINARS IN CANCER BIOLOGY (2019)
Phospho-mTOR expression in human glioblastoma microglia-macrophage cells
Lucia Lisi et al.
NEUROCHEMISTRY INTERNATIONAL (2019)
NF-κB, Mesenchymal Differentiation and Glioblastoma
Bakhtiar Yamini
CELLS (2018)
Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence
Carmen Mecca et al.
DISEASE MARKERS (2018)
Metalloproteinases ADAM10 and ADAM17 Mediate Migration and Differentiation in Glioblastoma Sphere-Forming Cells
Elodie J. Siney et al.
MOLECULAR NEUROBIOLOGY (2017)
Blockade of CCR5 receptor prevents M2 microglia phenotype in a microglia-glioma paradigm
Emilia Laudati et al.
NEUROCHEMISTRY INTERNATIONAL (2017)
Expression of iNOS, CD163 and ARG-1 taken as M1 and M2 markers of microglial polarization in human glioblastoma and the surrounding normal parenchyma
L. Lisi et al.
NEUROSCIENCE LETTERS (2017)
The metalloproteinase ADAM10: A useful therapeutic target?
Sebastian Wetzel et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2017)
TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies
Howard A. Burris et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Exploiting Microglial Functions for the Treatment of Glioblastoma
Cinzia Dello Russo et al.
CURRENT CANCER DRUG TARGETS (2017)
Suppression of the invasive potential of Glioblastoma cells by mTOR inhibitors involves modulation of NFκB and PKC-α signaling
Goparaju Chandrika et al.
SCIENTIFIC REPORTS (2016)
mTOR: a pharmacologic target for autophagy regulation
Young Chul Kim et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Proinflammatory-activated glioma cells induce a switch in microglial polarization and activation status, from a predominant M2b phenotype to a mixture of M1 and M2a/B polarized cells
Lucia Lisi et al.
ASN NEURO (2014)
The mTOR kinase inhibitors polarize glioma-activated microglia to express a M1 phenotype
Lucia Lisi et al.
JOURNAL OF NEUROINFLAMMATION (2014)
Making new contacts: the mTOR network in metabolism and signalling crosstalk
Mitsugu Shimobayashi et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
mTOR and autophagy: A dynamic relationship governed by nutrients and energy
E. A. Dunlop et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2014)
ADAM17 promotes U87 glioblastoma stem cell migration and invasion
Xiangrong Chen et al.
BRAIN RESEARCH (2013)
ADAM17 promotes glioma cell malignant phenotype
Xuguang Zheng et al.
MOLECULAR CARCINOGENESIS (2012)
Current development of the second generation of mTOR inhibitors as anticancer agents
Hong-Yu Zhou et al.
CHINESE JOURNAL OF CANCER (2012)
Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human Lung carcinomas
Yoh Dobashi et al.
HUMAN PATHOLOGY (2011)
Protein and its Function Based on a Subcellular Localization
Jana Cmielova et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2011)
ADAM-10-Mediated N-Cadherin Cleavage Is Protein Kinase C-α Dependent and Promotes Glioblastoma Cell Migration
Zachary A. Kohutek et al.
JOURNAL OF NEUROSCIENCE (2009)
Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatment
Bing-Hua Jiang et al.
DRUG RESISTANCE UPDATES (2008)
Procaspase 3/p21 complex formation to resist Fas-mediated cell death is initiated as a result of the phosphorylation of p21 by protein kinase A
A Suzuki et al.
CELL DEATH AND DIFFERENTIATION (2000)
Share Paper
